As stated by Passaro et al. and Hendriks et al. in recent ESMO consensus panels of experts in lung cancer treatment, first-line third-generation EGFR TKIs such as osimertinib are the current standard of care in the treatment of advanced NSCLC harboring EGFR activating mutations [9,45], with excellent efficacy outcomes and safety profile leading also to relevant quality of life outcomes [10,11]. The gene discussed is EGFR; the disease is lung carcinoma.